KYKOF - Amgen and Kyowa Kirin in pact for experimental atopic dermatitis therapy

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced an agreement to jointly develop and commercialize KHK4083 an anti-OX40 fully human monoclonal antibody currently set for Phase 3 studies in atopic dermatitis with potential application in other autoimmune diseases.Per the terms, Amgen will make a $400M up-front payment to Kyowa Kirin in addition to future contingent milestone payments potentially worth up to an additional $850M as well as royalty payments on future global sales.Amgen will lead the development, manufacturing, and commercialization of KHK4083 for all global markets, except Japan, where Kyowa Kirin will retain all rights.The two companies will co-promote KHK4083 in the U.S. and Kyowa Kirin has opt-in rights to co-promote KHK4083 in certain other markets outside the U.S., including in Europe and Asia.Amgen and Kyowa Kirin will share the U.S. commercialization costs and global development costs except in Japan. Closing of the deal is subject to obtaining any necessary consents and

For further details see:

Amgen and Kyowa Kirin in pact for experimental atopic dermatitis therapy